By specifically binding to PD-1, LIBTAYO can “break” the inhibition of T cells by cancer cells, and T-cell receptor signals can be reactivated to restore anti-tumor activity, so as to enhance the killing ability of human immune system to cancer cells and achieve anti-cancer effect. The gene discussed is PDCD1; the disease is neoplasm.